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Summary
 
Recent evidence indicates that integrin engagement results in the activation of biochemical
signaling events important for regulating different cell functions, such as migration, adhesion,
proliferation, differentiation, apoptosis, and specific gene expression. Here, we report that 
 
b
 
1
integrin ligation on human natural killer (NK) cells results in the activation of Ras/mitogen-
activated protein kinase pathways. Formation of Shc–growth factor receptor–bound protein 2
(Grb2) and Shc–proline-rich tyrosine kinase 2–Grb2 complexes are the receptor-proximal
events accompanying the 
 
b
 
1 integrin–mediated Ras activation. In addition, we demonstrate
that ligation of 
 
b
 
1 integrins results in the stimulation of interferon 
 
g
 
 (IFN-
 
g
 
) production,
which is under the control of extracellular signal–regulated kinase 2 activation. Overall, our
data indicate that 
 
b
 
1 integrins, by delivering signals capable of triggering IFN-
 
g
 
 production,
may function as NK-activating receptors.
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N
 
atural killer (NK) cells, a small population of circulat-
ing and tissue-resident lymphocytes, play an impor-
tant role in the early phase of immune responses against
certain viruses, parasites, and microbial pathogens by ex-
hibiting cytotoxic functions and secreting a number of cy-
tokines such as IFN-
 
g
 
, TNF-
 
a
 
, and GM-CSF (1, 2).
It is becoming increasingly clear that the final outcome
of NK cell activity results from a balance between trigger-
ing and inhibitory receptors and ligands. In the last few
years, much attention has been given to the characteriza-
tion of inhibitory receptors recognizing MHC class I mole-
cules, named killer cell–inhibitory receptors (KIRs), while
knowledge about receptors delivering positive signals is less
advanced. Activating molecules include receptors belong-
ing to the integrin (LFA-1, 
 
a
 
4
 
b
 
1), Ig (CD16, CD2,
DNAX accessory molecule 1 [DNAM-1]), and C-type lec-
tin (NKRP-1, CD69) families (3–6). Recently, noninhibi-
tory isoforms of MHC class I receptors have also been de-
scribed (7–9), as well as the mechanisms by which they
transmit stimulatory signals (10).
Integrins are a large family of homologous cell surface
receptors that mediate cell–matrix and cell–cell interactions
(11, 12) and that are capable of transducing intracellular
signals (13–16). The integrin-mediated signaling events in-
clude stimulation of phosphoinositide metabolism, eleva-
tion of intracellular pH and Ca
 
2
 
1
 
 transients, activation of a
number of tyrosine kinases and protein kinase C isoforms,
and regulation of the small GTP-binding proteins belong-
ing to the Ras and Rho families. In addition, coupling of
integrin receptors to mitogen-activated protein kinase
(MAPK)
 
1
 
 pathways has been reported (17), and a role for
p21 Ras in the upstream events leading to extracellular sig-
nal–regulated kinase (Erk) activation has recently been
demonstrated (18, 19). Integrin-induced Ras activation has
been shown to involve the Shc-mediated recruitment of
the Grb2–mSos complex to the plasma membrane (18, 19).
Moreover, a role for p125 focal adhesion kinase (Fak) in
 
1
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 Erk, extracellular signal–regulated kinase;
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F(ab
 
9
 
)
 
2
 
; Grb2, growth factor–bound protein 2; GST, glutathione 
 
S
 
-trans-
ferase; Jnk, c-Jun NH
 
2
 
-terminal kinase; MAPK, mitogen-activated pro-
tein kinase; MBP, myelin basic protein; MEK, MAPK kinase; Pyk-2,
proline-rich tyrosine kinase 2.
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the integrin-mediated activation of the Ras-MAPK cascade
has been suggested, as formation of the Fak–Grb2–mSos
complex parallels activation of Erk kinases (20–22).
Several findings indicate that integrins can affect expres-
sion of several genes, including those encoding cytokines.
Adhesion of monocytes to extracellular matrix components
results in activation of IL-1
 
b
 
, TNF-
 
a
 
, IL-8, Gro-
 
a
 
, Gro-
 
b
 
,
and Gro-
 
g
 
 (23–27). In addition, 
 
a
 
v
 
b
 
3 interaction with
fibronectin (FN) and vitronectin enhances IL-4 and IL-2
production by murine 
 
g
 
/
 
d
 
 T cells and by a Th cell hybri-
doma, respectively (28, 29). In human T cells, LFA-1, 
 
a
 
4
 
b
 
1,
and 
 
a
 
5
 
b
 
1 provide a costimulus for the release of multiple
cytokines such as IL-2, IL-4, TNF-
 
a
 
, GM-CSF, and IFN-
 
g
 
(30-34) and similarly, LFA-1 costimulates CD16-triggered
TNF-
 
a
 
 production in human NK cells (35). Nonetheless,
information on the intracellular signaling events leading to
the control of gene expression by integrins has been pro-
vided so far only in epithelial and mesenchymal cells.
We have previously shown that peripheral blood human
NK cells express 
 
a
 
4
 
b
 
1 and 
 
a
 
5
 
b
 
1 as fibronectin receptors
(36) and 
 
a
 
6
 
b
 
1 as a laminin receptor (37), and that the ex-
pression and function of 
 
b
 
1 integrins are modulated upon
NK cell activation (37, 38). More recently, we have dem-
onstrated that clustering of 
 
b
 
1 integrins on human NK cells
transduces intracellular signals leading to activation of the
Fak-related nonreceptor tyrosine kinase Pyk-2, tyrosine
phosphorylation of paxillin (39), elevation of intracellular
calcium, and costimulation of NK cytotoxic functions (40).
In this study, we analyzed whether 
 
b
 
1 integrin ligation on
human NK cells results in the stimulation of the Ras/
MAPK signaling pathways and investigated the role of
these events in the production of IFN-
 
g
 
.
 
Materials and Methods
 
Antibodies and Reagents.
 
The following mouse mAbs were
used: anti-CD3 (Leu4), anti-CD16 (Leu11c), and anti-CD56
(Leu19) were purchased from Becton Dickinson (San Jose, CA).
Anti-CD16 (B73.1) mAb was provided by Dr. G. Trinchieri
(The Wistar Institute, Philadelphia, PA). Anti-CD56 (C218)
mAb was provided by Dr. A. Moretta (University of Genoa,
Genoa, Italy). Anti-
 
b
 
1 (4B4) was purchased from Coulter Corp.
(Hialeah, FL). The antiphosphotyrosine (anti-pTyr) mAb 4G10
was purchased from Upstate Biotechnology, Inc. (Lake Placid,
NY). The anti-Grb2 and anti-Shc mAbs and the affinity-purified
rabbit anti-Shc antiserum were obtained from Transduction Lab-
oratories (Lexington, KY). The affinity-purified antiserum against
Erk2 was obtained from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA). The anti-Ras (Y13-259) mAb and the rabbit antise-
rum against the synthetic peptides corresponding to residues 684–
762 of Pyk-2 (600) were provided by Dr. J. Schlessinger (New
York University Medical Center, New York). The affinity-puri-
fied rabbit antiserum against mouse Ig was purchased from
Zymed Laboratories, Inc. (South San Francisco, CA). Affinity-
purified (Fab
 
9
 
)
 
2
 
 fragments of goat anti–mouse Ig (GAM) were
purchased from Cappel Laboratories (Organon Teknika, West
Chester, PA). Glutathione 
 
S
 
-transferase (GST)–Jun fusion protein
coupled to glutathione agarose beads was a gift from Dr. C.J. Der
(University of North Carolina at Chapel Hill, NC).
Human plasma FN was purchased from GIBCO BRL (Gai-
thersburg, MD), and the 120- and 40-kD proteolytic fragments of
FN were purchased from Chemicon International, Inc. (Temec-
ula, CA).
 
Human NK Cell Preparation.
 
Cultured NK cells were obtained
by incubating for 10 d nylon nonadherent PBMC (4 
 
3 
 
10
 
5
 
 cells)
with irradiated (3,000 rads) RPMI 8866 cells (10
 
5
 
) as described
previously (38). On day 10, contaminating T cells were elimi-
nated by negative panning with anti-CD5 mAb, and the resulting
NK cell population was 
 
z
 
95% CD16
 
1
 
CD56
 
1
 
CD3
 
2
 
CD14
 
2
 
 as
assessed by immunofluorescence and cytofluorimetric analysis.
 
Cell Stimulation.
 
Human NK cells were resuspended in
RPMI 1640 serum-free medium (50 
 
3 
 
10
 
6
 
 cells/300 
 
m
 
l/tube)
and incubated with saturating doses of the appropriate mAb for
30 min at 4
 
8
 
C. After washing off the unbound antibody, cells
were resuspended in prewarmed RPMI 1640 medium and incu-
bated for different time periods with polystyrene beads (2.5-
 
m
 
m
diameter; Interfacial Dynamics Corporation, Portland, OR)
coated with GAM (1.5 
 
m
 
g/10
 
6
 
 cells) at 37
 
8
 
C (41). In some ex-
periments, human NK cells were resuspended in RPMI 1640 se-
rum-free medium (50 
 
3 
 
10
 
6
 
/300 
 
m
 
l/tube) and incubated for dif-
ferent time periods with polystyrene beads coated with human
plasma FN or its proteolytic fragments of 120 and 40 kD or with
BSA. When indicated, cells were pretreated (30 min at 37
 
8
 
C)
with MEK-1 inhibitor PD 098059 (Calbiochem-Novabiochem,
La Jolla, CA).
 
Immunoprecipitation and Immunoblot Analysis.
 
To estimate Ras
activation, human NK cells were starved for 3 h in phosphate-
free DMEM and labeled for 3 h with [
 
32
 
P]orthophosphate (0.5
mCi/ml, 4,500 Ci/mmol; ICN Biomedicals, Inc., Irvine, CA)
in phosphate-free DMEM supplemented with 0.1% phosphate-
free FCS. After stimulation, the cells were extracted and the im-
munoprecipitated samples subjected to Ras-GTP loading assay
as described previously (19). Nucleotides bound to Ras were
analyzed by TLC on polyethyleneimine-cellulose plates in 0.75
M K
 
2
 
HPO
 
4
 
, pH 3.5. Radioactivity in GDP and GTP was esti-
mated by PhosphorImager analysis (Molecular Dynamics, Sunny-
vale, CA).
To immunoprecipitate Shc and Pyk-2, stimulated and unstim-
ulated human NK cells were extracted in Triton lysis buffer
(50 mM Hepes, pH 7.5, 150 mM NaCl, 1% Triton X-100) contain-
ing 1 mM sodium orthovanadate, 2.5 mM sodium pyrophos-
phate, 25 mM sodium fluoride, 0.01% aprotinin, 4 mg/ml pep-
statin A, 10 mg/ml leupeptin, and 1 mM PMSF (all from Sigma
Chemical Co., St. Louis, MO) for 30 min on ice. Immuno-
precipitation, SDS-PAGE, and immunoblotting analysis were
performed as described previously (41). Nitrocellulose-bound
antibodies were detected by enhanced chemiluminescence (ECL;
Nycomed Amersham plc, Little Chalfont, Bucks, UK).
 
In Vitro Kinase Assay.
 
To examine Erk activity, cells were
extracted with NP-40 lysis buffer (50 mM Hepes, pH 7.5, 150
mM NaCl, 1% NP-40, 1 mM EDTA) containing phosphatase
and protease inhibitors for 30 min on ice. Endogenous Erk2 was
immunoprecipitated with anti-Erk2 antibodies and subjected to
in vitro kinase assay. The kinase reaction was initiated by adding
to the immunoprecipitate 25 
 
m
 
l of kinase buffer (25 mM Tris, pH
7.5, 12.5 mM 
 
b
 
-glycerophosphate, 7.5 mM MgCl
 
2
 
, 20 
 
m
 
M cold
ATP, 0.5 mM sodium orthovanadate) containing 5 
 
m
 
Ci of [
 
g
 
-
 
32
 
P]ATP (4,500 Ci/mmol; ICN Biomedicals, Inc.) and 2.5 
 
m
 
g of
myelin basic protein (MBP; Sigma Chemical Co.). After 30 min
of incubation at 30
 
8
 
C, the samples were boiled in sample buffer
and separated by SDS-PAGE. The gels were dried, and the 
 
32
 
P-
labeled proteins were made visible by autoradiography. 
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To analyze the activation of Jnk, cells were extracted for 30
min on ice with modified Triton lysis buffer (25 mM Hepes, pH
7.5, 300 mM NaCl, 0.1% Triton X-100, 0.2 mM EDTA, 20 mM
 
b
 
-glycerophosphate, 1.5 mM MgCl
 
2
 
, 0.5 mM dithiothreitol)
containing phosphatase and protease inhibitors. Endogenous Jnk
was precipitated with 3 
 
m
 
g of GST–Jun fusion protein coupled to
glutathione agarose beads. After washing, the beads were incu-
bated with 25 ml of kinase buffer containing 5 mCi of [g-32P]ATP
(4,500 Ci/mmol; ICN Biomedicals, Inc.). After 30 min of incu-
bation at 308C, the samples were boiled in sample buffer and sep-
arated by SDS-PAGE. The gels were dried, and the 32P-labeled
proteins were made visible by autoradiography.
Northern Blot Analysis. Total RNA was extracted using RNAfast
(Molecular Systems, San Diego, CA), size-fractionated in 1%
agarose/formaldehyde gels, transferred by capillarity onto nitro-
cellulose filters, baked at 808C for 2 h, and hybridized to cDNA
probes specific for human IFN-g and b-actin. cDNA probes
were labeled with [a-32P]dCTP (3,000 Ci/mmol; ICN Biomedi-
cals, Inc.) by random priming (Amersham Pharmacia Biotech,
Uppsala, Sweden). RNA was visualized in ethidium bromide–
stained gels, and the amount of RNA loaded was determined
after hybridization to b-actin cDNA. Filters were exposed to
X-AR film (Eastman Kodak, Rochester, NY) for autoradiogra-
phy. Levels of expression of each mRNA species were quanti-
tated as above.
IFN-g Production Assay. Unstimulated or stimulated NK cells
were seeded in duplicate wells of flat-bottomed plates (107 cells/
well; Costar Corp., Cambridge, MA) in medium containing 1%
BSA. After incubation (24 h, 378C in a 5% CO2 atmosphere), cell-
free supernatants were collected. IFN-g concentration was quanti-
tated with an ELISA kit (EuroClone, Torquay, Devon, UK).
Results
Activation of Ras upon Cross-linking of b1 Integrins on Hu-
man NK Cells. GTP-loading experiments were performed
to examine if ligation of b1 integrins on human NK cells
results in activation of Ras. After in vivo labeling with
[32P]orthophosphate, human NK cells were incubated with
saturating concentrations of anti-b1 or anti-CD56 control
mAb and stimulated for the indicated times at 378C with
polystyrene beads coated with GAM F(ab9)2 fragments. As
shown in Fig. 1, chromatographic analysis of nucleotides
bound to Ras indicated that b1 integrin stimulation results
in a threefold increase in the proportion of GTP-bound
Ras (from 8 to 21%). Ras activation was rapid, peaking at
5 min and returning to basal levels after 40 min. Anti-CD56
mAb–treated control samples showed a p21 Ras GTP to
GDP plus GTP ratio comparable to that of the untreated
sample (not shown).
These results indicate that cross-linking of b1 integrins
on human NK cells causes activation of Ras.
Cross-linking of b1 Integrins on Human NK Cells Induces
Shc Tyrosine Phosphorylation and Grb2 Association. Integrin-
induced Ras activation involves tyrosine phosphorylation
of the adaptor protein Shc and Shc-mediated recruitment
of the adaptor protein Grb2 (18, 19). Since Grb2 is stably
associated with the Ras-GTP exchange factor mSos, the as-
sociation of Grb2 with Shc is likely to bring mSos in close
proximity to its target Ras (42). To investigate whether li-
gation of b1 integrins on NK cells results in tyrosine phos-
phorylation of Shc, human NK cells were stimulated with
anti-b1 or anti-CD56 mAb as above. Anti-Shc immuno-
precipitates were examined by immunoblotting with anti-
pTyr mAb. Marked tyrosine phosphorylation of both the
46- and 52-kD isoforms of Shc was detected after b1 inte-
grin cross-linking (Fig. 2). b1 integrin–mediated Shc phos-
phorylation was rapid and persistent, in that it peaked at 5
min and declined at 40 min. No changes in the phosphory-
lation status of Shc were observed in untreated or anti-
Figure 1. Kinetics of Ras acti-
vation by triggering of human
NK cells via b1 integrins. TLC
of the nucleotides eluted from
p21ras immunoprecipitates of
[32P]orthophosphate-labeled NK
cells. Cells were stimulated for
the indicated times with appro-
priate doses of anti-b1 (4B4) or
anti-CD56 (C218) mAb at 378C
before lysis, and immunoprecipi-
tation of p21ras with Y13-259
mAb was performed as described
(reference 19). The positions at
which GTP and GTP standards
run are indicated, as well as ori-
gin position (Ori.). Numbers in-
dicate the molar ratio of GTP to total nucleotides from quantitation by di-
rect scanning for b radiation of the same experiment. These results are
representative of three independent experiments.
Figure 2. Ligation of b1 integrins on NK cells induces tyrosine phos-
phorylation of Shc and recruitment of Grb2. Human NK cells were stim-
ulated with control medium or anti-b1 (4B4) or anti-CD56 (C218) mAb
for the indicated times at 378C. Cell lysates (50 3 106 cells/sample) were
subjected to immunoprecipitation (IP) with anti-Shc polyclonal antibody.
The resulting protein complexes were resolved by 10% SDS-PAGE,
transferred to nitrocellulose, and immunoblotted with either anti-pTyr
(4G10) or anti-Grb2 antibody. Sizes are indicated in kilodaltons. These
results are representative of three independent experiments.1270 b1 Integrins Induce IFN-g Production in NK Cells
CD56 mAb–treated NK cells used as control. Interestingly,
an additional tyrosine-phosphorylated protein of z145 kD
was consistently coimmunoprecipitated with Shc from b1 in-
tegrin–stimulated NK cell lysates; tyrosine phosphorylation of
Shc and p145 occurred with the same kinetics (Fig. 2). The
nature of this protein has not been investigated, but it is likely
to correspond to one of the isoforms of the lipid phosphatase
Ship, which combines with the Shc phosphotyrosine-bind-
ing (PTB) domain upon tyrosine phosphorylation (43). To
examine the possibility that tyrosine-phosphorylated Shc
associates with the SH2 domain–containing adaptor protein
Grb2, Shc immunoprecipitates were immunoblotted with an
anti-Grb2 antibody. The results indicate that Grb2 forms a
complex with Shc in b1 integrin–stimulated NK cells. No
Shc–Grb2 association was observed in NK cells untreated or
treated with anti-CD56 mAb used as control (Fig. 2).
Similar data were obtained upon cross-linking of a4b1 and
a5b1 FN receptors with polystyrene beads coated with FN
or its 120- and 40-kD proteolytic fragments recognized by
a5b1 and a4b1, respectively (Fig. 3). These results indicate
that cross-linking of b1 integrin FN receptors on human NK
cells induces Shc tyrosine phosphorylation and its association
with Grb2. The time course of Shc phosphorylation and
Grb2 association strictly parallels the b1 integrin–mediated
p21 Ras activation, suggesting that the formation of the
Shc-Grb2 complex is important for Ras activation.
Cross-linking of b1 Integrins on Human NK Cells Induces
Shc and Grb2 Association with Pyk-2. The ability of the Fak
family members to combine with Grb2 upon integrin
engagement has been shown, and a role for p125Fak in the
integrin-mediated activation of the Ras-MAPK cascade has
been suggested (20, 21). We reported recently that human
peripheral blood NK cells express Pyk-2 and not p125Fak,
and that ligation of b1 FN receptors results in Pyk-2 acti-
vation (39). To investigate whether Pyk-2 can associate
with Shc and Grb2 upon b1 integrin cross-linking, human
NK cells were stimulated with anti-b1 or anti-CD56 mAb
as above. Pyk-2 immunoprecipitates were then analyzed
for the presence of Shc and Grb2 by immunoblotting with
specific mAbs. As shown in Fig. 4, the 46-kD isoform of
Shc and the adaptor protein Grb2 were detected in the
Pyk-2 immunoprecipitates after b1 integrin cross-linking.
Shc and Grb2 association to Pyk-2 was observed at 5 min
and was still evident at 15 min; formation of this complex
parallels Pyk-2 tyrosine phosphorylation. No association of
Shc and Grb2 with Pyk-2 was observed in untreated or
control mAb–treated NK cells.
These results suggest that tyrosine-phosphorylated Pyk-2
forms a complex with Shc and Grb2 upon stimulation of
NK cells through b1 integrins, suggesting that Pyk-2 may
cooperate with the Shc–Grb2 complex to fully activate Ras
in response to integrin ligation.
Ligation of b1 Integrins on Human NK Cells Causes Activa-
tion of MAPK Signaling Pathway. We next examined if li-
Figure 3. Ligation of b1 integrin FN receptors on NK cells induces ty-
rosine phosphorylation of Shc and recruitment of Grb2. Human NK cells
were stimulated with control medium, anti-b1 (4B4) or anti-CD56
(C218) mAb, FN or its 120- and 40-kD proteolytic fragments, or BSA for
the indicated times at 378C. Cell lysates (50 3 106 cells/sample) were sub-
jected to immunoprecipitation (IP) with anti-Shc polyclonal antibody.
The resulting protein complexes were resolved by 10% SDS-PAGE,
transferred to nitrocellulose, and immunoblotted with anti-pTyr (4G10),
anti-Grb2, or anti-Shc antibody. Sizes are indicated in kilodaltons. These
results are representative of three independent experiments.
Figure 4. Cross-linking of b1 integrins on human NK cells induces as-
sociation of Pyk-2 with Shc and Grb2. Human NK cells were stimulated
with control medium or anti-b1 (4B4) or anti-CD56 (C218) mAb for the
indicated times at 378C. Cell lysates (50 3 106 cells/sample) were sub-
jected to immunoprecipitation (IP) with anti–Pyk-2 polyclonal antibody.
The resulting protein complexes were resolved by 8% SDS-PAGE, trans-
ferred to nitrocellulose, and immunoblotted with anti-pTyr (4G10), anti-
Shc, anti-Grb2, or anti–Pyk-2 antibody. Sizes are indicated in kilodaltons.
These results are representative of three independent experiments.1271 Mainiero et al.
gation of b1 integrins on human NK cells results in activa-
tion of Erk and Jnk. Human NK cells were stimulated with
anti-b1 or anti-CD56 mAb and subjected to Erk2 and Jnk
kinase assay. As shown in Fig. 5, b1 integrin stimulation
causes a significant activation of Erk2 (A) and Jnk (B). This
activation is already evident at 1 min and still persistent at
20 min. In contrast, anti-CD56 control mAb treatment did
not result in any significant activation of Erk2 or Jnk.
These data indicate that ligation of b1 integrins on hu-
man NK cells causes a significant and persistent activation
of Erk and Jnk.
Ligation of b1 Integrins on Human NK Cells Stimulates
IFN-g Production and Requires Erk2 Activation. We first ex-
amined if ligation of b1 integrins on human NK cells can
affect IFN-g mRNA expression. Northern blot analysis
was performed by using total RNA from human NK cells
stimulated with anti-b1 or anti-CD56 mAb. Fig. 6 shows
that b1 integrin ligation induces IFN-g mRNA expression,
which was maximal at 30 min and declined at 3 h after
stimulation. Treatment of human NK cells with anti-CD56
mAb used as control did not influence IFN-g mRNA ex-
pression (Fig. 6 A).
To investigate whether b1 integrin–induced IFN-g
mRNA expression is under the control of Erk activation,
we used the synthetic inhibitor PD 098059, which specifi-
cally prevents activation of the Erk-activating kinase MEK-1
(44, 45). PD 098059, at the 50 mM concentration that
completely inhibits b1 integrin–induced Erk2 activation
(not shown), abrogated the stimulation of IFN-g mRNA
expression. The same concentration of PD 098059 did not
affect IFN-g mRNA levels in human NK cells treated with
anti-CD56 control mAb (Fig. 6 B).
Finally, we evaluated if ligation of b1 integrins on hu-
man NK cells stimulates IFN-g production by testing the
presence of this cytokine in the supernatants of NK cells,
either untreated or treated for 24 h at 378C with anti-b1 or
anti-CD56 control mAb. As shown in Fig. 7, b1 integrin
Figure 5. Activation of Erk2 and Jnk by b1 integrin cross-linking on
human NK cells. Human NK cells were stimulated with control medium
or anti-b1 (4B4) or anti-CD56 (C218) mAb for the indicated times at
378C. (A) Cell lysates (50 3 106 cells/sample) were immunoprecipitated
with anti-Erk2 polyclonal antibody and subjected to in vitro kinase assay
using MBP as substrate. The resulting protein complexes were resolved
by 15% SDS-PAGE. The position of phosphorylated MBP is indicated.
The amount of Erk2 immunoprecipitated from each sample was evalu-
ated by immunoblotting with anti-Erk2 antibody. (B) Jnk was precipi-
tated by using glutathione beads coated with GST–Jun fusion protein and
subjected to in vitro kinase assay. The resulting protein complexes were re-
solved by 10% SDS-PAGE. The position of phosphorylated GST–Jun is in-
dicated. These results are representative of three independent experiments.
Figure 6. Erk2 activation controls b1 integrin–induced IFN-g mRNA
expression in human NK cells. (A) Total RNA was extracted from hu-
man NK cells stimulated with anti-b1 (4B4) or anti-CD56 (C218) mAb
for the indicated times at 378C. Northern blot analysis was performed us-
ing a cDNA probe specific for human IFN-g. (B) Human NK cells were
incubated for 30 min at 378C with 30 mM PD 098059 (1) or with
DMSO (vehicle; 2) and then stimulated with anti-b1 (4B4) or anti-
CD56 (C218) mAb for 1 h. Total RNA was extracted and subjected to
Northern blot analysis using cDNA probes specific for human IFN-g (top)
or b-actin (bottom).
Figure 7. Erk2 activation controls b1 integrin–induced IFN-g cyto-
kine production in human NK cells. Human NK cells were incubated for
30 min at 378C with 30 mM PD 098059 (1) or with DMSO (vehicle; 2)
and then stimulated with anti-b1 (4B4) or anti-CD56 (C218) mAb for 24 h
at 378C in a 5% CO2 atmosphere in duplicate wells of flat-bottomed
plates (107 cells/well) in medium containing 1% BSA. After incubation,
cell-free supernatants were collected. IFN-g concentration in the super-
natants was quantitated by ELISA.1272 b1 Integrins Induce IFN-g Production in NK Cells
cross-linking resulted in induction of IFN-g production at
levels comparable to those induced by CD16 engagement
(not shown). In contrast, treatment of human NK cells
with anti-CD56 mAb used as control did not stimulate
IFN-g production.
The induction of IFN-g synthesis required the activity
of Erk2 as shown by the ability of PD 098059 to com-
pletely inhibit b1 integrin–induced cytokine production
(Fig. 7).
These findings indicate that ligation of b1 integrins on
human NK cells stimulates IFN-g production, and that this
event requires Erk2 activation.
Discussion
The ability of integrins to cause activation of Ras has
been previously described in several adherent primary cells
and cell lines (18, 19). In regard to the immune system,
there is only one report showing that a2b1 triggers Ras ac-
tivation in Jurkat T leukemia cells (46). Here, we demon-
strate that b1 integrin ligation on human peripheral blood
NK cells results in activation of the Ras/MAPK pathway,
which is involved in integrin-triggered IFN-g production.
In addition, we provide information on the receptor-prox-
imal events accompanying the b1 integrin–mediated Ras
activation, namely tyrosine phosphorylation of Shc and its
association with Grb2, and the association of tyrosine-
phosphorylated Pyk-2 with Grb2 and Shc.
Tyrosine phosphorylation of both the 46- and 52-kD
isoforms of Shc was observed after mAb-mediated cross-
linking of b1 integrins, as well as upon interaction of NK
cells with FN and its proteolytic 120- and 40-kD frag-
ments, which are recognized by a5b1 and a4b1, respec-
tively. The time course of b1 integrin–triggered Shc phos-
phorylation strictly paralleled Ras activation, suggesting
that the formation of the Shc–Grb2 complex is important
in this event.
These results are in accordance with previous studies in-
dicating the involvement of the Shc–Grb2 complex in Ras
activation upon engagement of avb3, b4, or several b1 in-
tegrins on various adherent cell types (18, 19, 41).
Integrin-mediated activation of Ras has also been sug-
gested to involve the nonreceptor tyrosine kinase p125Fak,
and the formation of the Fak–Grb2–mSos complex upon
cell adhesion to FN has been described (20, 22). No data
are available yet on the involvement of the recently discov-
ered member of the Fak family, Pyk-2, in the activation of
Ras through integrins, although the association of Pyk-2
with Grb2 has been observed in FN-activated COS cells
(47). However, recent observations indicate that Pyk-2
regulates Ras in response to neurotransmitters, inflamma-
tory cytokines, and cellular stresses by recruiting the Grb2–
mSos complex to the plasma membrane (48). We have re-
cently demonstrated that human peripheral blood NK cells
express Pyk-2 but not p125Fak, and that tyrosine phos-
phorylation of Pyk-2 occurs rapidly after ligation of b1 inte-
grins by natural ligands or specific mAbs (39). Here we
show that integrin ligation induces association of tyrosine-
phosphorylated Pyk-2 with Grb2 and Shc. Interestingly,
only the 46-kD isoform of Shc was detected in Pyk-2 im-
munoprecipitates, suggesting that the p46 and p52 Shc may
have different functional properties. In line with this hy-
pothesis, it has been reported that p66 Shc, which is mainly
expressed in epithelial cells, mediates opposite effects on
the epidermal growth factor (EGF) receptor/MAPK/Fos
signaling pathways with respect to the other splicing iso-
forms (49).
Overall, our results suggest that the formation of the
Shc–Grb2 and Shc–Pyk-2–Grb2 complexes may couple b1
integrins to the Ras pathway in human NK cells. The rela-
tive contribution of Shc–Grb2 and Shc–Pyk-2–Grb2 com-
plexes in the signaling events leading to integrin-mediated
activation of Ras is currently unknown. Upon integrin en-
gagement, both tyrosine-phosphorylated Shc and Pyk-2
may bind to the SH2 domain of Grb2 (22, 48, 50);
whether Pyk-2 interacts directly with Shc has not yet been
defined. Knowledge of the molecular basis regulating the
association of Shc with Grb2-associated Pyk-2 is necessary
for a better understanding of whether Shc and Pyk-2 repre-
sent additive complementary pathways required to fully ac-
tivate Ras in response to integrin ligation, or if one of these
pathways is dominant and the other redundant.
The results of this study also indicate that ligation of b1
integrins on human NK cells stimulates the enzymatic ac-
tivities of both Erk2 and Jnk, the last kinases of MAPK cas-
cades controlled by Ras activation.
Activation of Erk and Jnk in response to integrin stimu-
lation has been reported previously (17–19, 51). However,
the majority of these studies were performed in adherent
cell types, including primary human keratinocytes, endo-
thelial cells, and 3T3 fibroblasts. In the immune system, it
has been reported that a4b1 costimulates (pp45) MAPK
activation in resting T cells (52), but no evidence is avail-
able on the ability of integrins to activate Jnk.
Control of Erk activation has been shown to involve Shc
and Ras as indicated by the ability of their dominant nega-
tive forms to prevent Erk2 activation in response to cell ad-
hesion to fibronectin or laminin (18, 19, 53). However,
Ras-independent signaling events have also been impli-
cated in control of MAPK activation (54). Jnk activation
upon integrin ligation involves multiple pathways, since it
is prevented by either Ras and Rac dominant negative
forms or the phosphatidylinositol 3-kinase inhibitor, wort-
mannin (19). Overall, it is conceivable that Ras activation
may be a crucial event controlling b1 integrin–triggered
MAPK cascades in NK cells.
Finally, we provide evidence that ligation of b1 integrins
on human NK cells results in the stimulation of IFN-g
mRNA expression and production, which are under the
control of Erk2 activation as shown by the use of the spe-
cific MEK-1 inhibitor, PD 98059. Similarly, a role for
Erk2 activation in the control of IFN-g synthesis in T cells
triggered through the TCR complex has been recently
demonstrated (55). The involvement of Erk in the regula-
tion of IFN-g production may be related to its ability to
activate c-Fos transcription and to regulate the formation of1273 Mainiero et al.
the activating protein (AP)-1 heterodimer (56), which is
involved in the control of the IFN-g gene promoter (57,
58). In support of this hypothesis, several studies indicate
that integrins activate several transcriptional factors (25, 31,
59, 60); furthermore, recent studies in a4b1-stimulated
monocytes have demonstrated an association between Erk
activation and nuclear factor (NF)-kB translocation, which
leads to the expression of the tissue factor gene (61).
Our data indicate that b1 integrins, by delivering signals
capable of triggering IFN-g production, may function as
NK-activating receptors. In a previous study, we have
shown that cross-linking of a4b1 and a5b1 by specific
mAbs or by the natural ligands vascular cell adhesion mole-
cule 1 (VCAM-1) and FN costimulates but does not trigger
natural cytotoxicity (40). Taken together, these results sug-
gest that different receptor signaling thresholds and/or dif-
ferent signaling events are required to elicit distinct NK cell
functions: it is possible that b1 integrin–mediated signaling
does not reach the threshold for induction of NK cytotox-
icity, or that b1 integrins are unable to transmit the signal(s)
required for the activation of the NK lytic program. In this
regard, ligation of b1 integrins on NK cells does not stimu-
late phospholipase Cg (PLC-g) activation and inositol-
1,4,5-triphosphate (PtdIns(1,4,5)P3 generation [Milella, M.,
personal communication]), a signaling pathway triggered
by the NK receptors capable of activating the cytotoxic
function. Furthermore, in accordance with this evidence,
certain target cell lines resistant to NK cell lysis and unable
to stimulate detectable phosphoinositide turnover were found
to be capable of inducing IFN-g production, although the
basis of this phenomenon remains unclear (Perussia, B.,
personal communication).
What is the pathophysiological relevance of IFN-g pro-
duced by NK cells in response to b1 integrin stimulation?
b1 integrins have been shown to control NK cell adhesion
to endothelial cells and migration of NK cells into the nor-
mal and neoplastic tissues (62–64). Based on our data, it can
be hypothesized that IFN-g produced by NK cells upon
interaction with activated endothelium or extracellular ma-
trix components may contribute to affect the local inflam-
matory reaction by regulating several functions of endothe-
lial cells, including expression of ICAM-1 and VCAM-1
adhesion receptors, cytokine release, and nitric oxide pro-
duction (65, 66). Finally, IFN-g production by NK cells in
response to b1 integrins may be relevant for the antiviral
activity exerted by the NK cells at the tissue level, in par-
ticular in the liver. It has been recently reported (67) that
NK cells control murine CMV infection in the liver by se-
creting IFN-g, which exerts its antiviral action through the
induction of nitric oxide synthesis; it has also been sug-
gested that unlike in the spleen, NK cell–dependent resis-
tance to murine CMV infection in this organ does not re-
quire NK cell contact with virus-modified target cells.
Thus, integrins may be indicated as one of the receptors
triggering IFN-g synthesis by liver NK cells which closely
interact with the endothelial cells in the hepatic sinusoids.
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